Larvol Delta - Safety-profile-of-ianalumab-in-Sj246gren39s-disease-Observations-from-the-pooled-results-of-the-phase-3-trials-NEPTUNUS1-and-NEPTUNUS2-up-to-52-weeks

ianalumab (VAY736) - Novartis

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1898567&mode=presInfo

Thomas Grader-Beck, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next